Diuretic Combination Therapy in Acute Heart Failure: An Updated Review

Alessandro      Villaschi; Marta      Pellegrino; Gianluigi      Condorelli; Mauro      Chiarito

doi:10.2174/0113816128316596240625110337

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Loop diuretics are the cornerstone of decongestive therapy in patients presenting with acute heart failure and have been extensively studied in randomized clinical trials. Therefore, in current guidelines, they are the only drug with a class I recommendation to treat signs and symptoms of congestion when present. However, the percentage of patients achieving successful decongestion is suboptimal, and diuretic resistance frequently develops. Patients with a poor response to loop diuretics and those discharged with residual signs of congestion are characterized by a worse prognosis over time. Recently, a renovated interest in different diuretic classes sprouted among heart failure researchers in order to improve decongestion strategies and ameliorate short- and long-term clinical outcomes. Randomized clinical trials investigating associations among diuretic classes and loop diuretics have been performed but yielded variable results. Therefore, despite initial evidence of a possible benefit from some of these compounds, a definite way to approach diuretic resistance via diuretic combination therapy is still missing. The aim of this review is to summarize current clinical evidence on the use of diuretic combination therapy in patients with acute heart failure and to suggest a possible approach to avoid or counteract diuretic resistance.

[1]
Arrigo M, Jessup M, Mullens W, et al. Acute heart failure. Nat Rev Dis Primers  2020; 6(1): 16.
 [http://dx.doi.org/10.1038/s41572-020-0151-7]

[2]
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2021; 42(36): 3599-726.
 [http://dx.doi.org/10.1093/eurheartj/ehab368] [PMID: 34447992]

[3]
Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion  a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail  2019; 21(2): 137-55.
 [http://dx.doi.org/10.1002/ejhf.1369] [PMID: 30600580]

[4]
Moon KT. Diuretic strategies in persons with acute decompensated heart failure. Am Fam Physician  2012; 85(9): E1.
 [http://dx.doi.org/10.1056/NEJMOA1005419/SUPPL_FILE/NEJMOA1005419_DISCLOSURES.PDF]

[5]
Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med  2012; 367(24): 2296-304.
 [http://dx.doi.org/10.1056/NEJMoa1210357] [PMID: 23131078]

[6]
Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension  2020; 76(4): 1045-54.
 [http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15205] [PMID: 32829662]

[7]
Rubio-Gracia J, Demissei BG, ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol  2018; 258: 185-91.
 [http://dx.doi.org/10.1016/j.ijcard.2018.01.067] [PMID: 29544928]

[8]
Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail  2015; 17(11): 1172-81.
 [http://dx.doi.org/10.1002/ejhf.344] [PMID: 26417699]

[9]
Pagnesi M, Ghiraldin D, Vizzardi E, et al. Detailed assessment of the “i need help” criteria in patients with heart failure: Insights from the HELP-HF registry. Circ Heart Fail  2023; 16(12): e011003.
 [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.123.011003] [PMID: 37909222]

[10]
Rao VS, Ivey-Miranda JB, Cox ZL, et al. Natriuretic equation to predict loop diuretic response in patients with heart failure. J Am Coll Cardiol  2021; 77(6): 695-708.
 [http://dx.doi.org/10.1016/j.jacc.2020.12.022] [PMID: 33573739]

[11]
Pellegrino M, Villaschi A, Ghianda D, et al. Urinary sodium-guided intravenous diuretic therapy in acute heart failure: Transitioning from art to science? J Card Fail  2023; 29(12): 1678-82.
 [http://dx.doi.org/10.1016/j.cardfail.2023.07.012] [PMID: 37582420]

[12]
ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: A pragmatic randomized trial. Nat Med  2023; 29(10): 2625-32.
 [http://dx.doi.org/10.1038/s41591-023-02532-z] [PMID: 37640861]

[13]
Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med  2022; 387(13): 1185-95.
 [http://dx.doi.org/10.1056/NEJMoa2203094] [PMID: 36027559]

[14]
a) Yeoh SE, Osmanska J, Petrie MC, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J  2023; 44(31): 2966-77.
 [http://dx.doi.org/10.1093/eurheartj/ehad341] [PMID: 37210742]; 
b) Cox ZL, Collins SP, Hernandez GA et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol  2024; 83(14): 1295-306.
 [http://dx.doi.org/10.1016/j.jacc.2024.02.009] [PMID: 38569758]

[15]
Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: The CLOROTIC trial. Eur Heart J  2023; 44(5): 411-21.
 [http://dx.doi.org/10.1093/eurheartj/ehac689] [PMID: 36423214]

[16]
Piardi DS, Butzke M, Mazzuca ACM, et al. Effect of adding hydrochlorothiazide to usual treatment of patients with acute decompensated heart failure: A randomized clinical trial. Sci Rep  2021; 11(1): 16474.
 [http://dx.doi.org/10.1038/s41598-021-96002-6]

[17]
Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J  2021; 232: 116-24.
 [http://dx.doi.org/10.1016/j.ahj.2020.10.071] [PMID: 33144086]

[18]
Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. Front Med  2021; 8: 777861.
 [http://dx.doi.org/10.3389/fmed.2021.777861] [PMID: 34988095]

[19]
Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care  2014; 37(6): 1650-9.
 [http://dx.doi.org/10.2337/dc13-2105] [PMID: 24722494]

[20]
Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab  2014; 16(2): 147-58.
 [http://dx.doi.org/10.1111/dom.12188] [PMID: 23906415]

[21]
Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther  2009; 85(5): 513-9.
 [http://dx.doi.org/10.1038/clpt.2008.250] [PMID: 19129749]

[22]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med  2019; 380(4): 347-57.
 [http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]

[23]
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med  2019; 381(21): 1995-2008.
 [http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]

[24]
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet  2022; 400(10354): 757-67.
 [http://dx.doi.org/10.1016/S0140-6736(22)01429-5] [PMID: 36041474]

[25]
Gitto M, Villaschi A, Federici M, Condorelli G, Stefanini GG. The emerging role of sodium-glucose cotransporter 2 inhibitors in heart failure. Curr Pharm Des  2023; 29(7): 481-93.
 [http://dx.doi.org/10.2174/1381612829666230217143324] [PMID: 36799420]

[26]
Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation  2022; 146(18): 1383-405.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061732] [PMID: 36315602]

[27]
Feig PU. Cellular mechanism of action of loop diuretics: Implications for drug effectiveness and adverse effects. Am J Cardiol  1986; 57(2): A14-9.
 [http://dx.doi.org/10.1016/0002-9149(86)91001-5] [PMID: 3511652]

[28]
Arumugham VB, Shahin MH. Therapeutic Uses of Diuretic Agents. StatPearls Publishing 2023.

[29]
Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure. J Am Coll Cardiol  2020; 75(10): 1178-95.
 [http://dx.doi.org/10.1016/j.jacc.2019.12.059] [PMID: 32164892]

[30]
Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. V2 receptor antagonism with tolvaptan in heart failure. Expert Opin Investig Drugs  2007; 16(10): 1639-47.
 [http://dx.doi.org/10.1517/13543784.16.10.1639] [PMID: 17922627]

[31]
Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev  2009; 14(2): 75-82.
 [http://dx.doi.org/10.1007/s10741-008-9108-8] [PMID: 18766438]

[32]
Cox ZL, Testani JM. Loop diuretic resistance complicating acute heart failure. Heart Fail Rev  2020; 25(1): 133-45.
 [http://dx.doi.org/10.1007/s10741-019-09851-9] [PMID: 31520280]

[33]
Singh D, Shrestha K, Testani JM, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail  2014; 20(6): 392-9.
 [http://dx.doi.org/10.1016/j.cardfail.2014.03.006] [PMID: 24704538]

[34]
Testani JM, Hanberg JS, Cheng S, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail  2016; 9(1): e002370.
 [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002370] [PMID: 26721915]

[35]
Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure. JACC Heart Fail  2020; 8(3): 157-68.
 [http://dx.doi.org/10.1016/j.jchf.2019.09.012] [PMID: 31838029]

[36]
Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail  2014; 7(2): 261-70.
 [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000895] [PMID: 24379278]

[37]
Brinkley DM Jr, Burpee LJ, Chaudhry SP, et al. Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit. J Card Fail  2018; 24(6): 349-54.
 [http://dx.doi.org/10.1016/j.cardfail.2018.01.009] [PMID: 29410227]

[38]
Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome-an analysis from RELAX-AHF. Eur J Heart Fail  2014; 16(11): 1230-40.
 [http://dx.doi.org/10.1002/ejhf.170] [PMID: 25287144]

[39]
Valente MAE, Voors AA, Damman K, et al. Diuretic response in acute heart failure: Clinical characteristics and prognostic significance. Eur Heart J  2014; 35(19): 1284-93.
 [http://dx.doi.org/10.1093/eurheartj/ehu065] [PMID: 24585267]

[40]
ter Maaten JM, Dunning AM, Valente MAE, et al. Diuretic response in acute heart failure: An analysis from ASCEND-HF. Am Heart J  2015; 170(2): 313-321.e4.
 [http://dx.doi.org/10.1016/j.ahj.2015.05.003] [PMID: 26299229]

[41]
Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA  2013; 310(23): 2533-43.
 [http://dx.doi.org/10.1001/jama.2013.282190] [PMID: 24247300]

[42]
Gottlieb SS, Stebbins A, Voors AA, et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: Results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol  2013; 62(13): 1177-83.
 [http://dx.doi.org/10.1016/j.jacc.2013.04.073] [PMID: 23747790]

[43]
Ikeda Y, Ishii S, Maemura K, et al. Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. ESC Heart Fail  2021; 8(5): 4067-76.
 [http://dx.doi.org/10.1002/ehf2.13525] [PMID: 34323025]

[44]
Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Heart  1994; 72(2 Suppl) (Suppl.): S40-3.
 [http://dx.doi.org/10.1136/hrt.72.2_Suppl.S40] [PMID: 7946757]

[45]
Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: Shift in dose-response curves. Clin Pharmacol Ther  1980; 28(2): 182-6.
 [http://dx.doi.org/10.1038/clpt.1980.148] [PMID: 7398185]

[46]
Koeppen BM, Stanton BA. Physiology of diuretic action. Ren Physiol  2013; 10(3-4): 167-78.
 [http://dx.doi.org/10.1016/B978-0-323-08691-2.00010-7] [PMID: 3452853]

[47]
Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol  1997; 29(3): 367-72.
 [http://dx.doi.org/10.1097/00005344-199703000-00010] [PMID: 9125675]

[48]
Imiela T, Budaj A. Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: A pilot study. Clin Drug Investig  2017; 37(12): 1175-81.
 [http://dx.doi.org/10.1007/s40261-017-0577-1] [PMID: 28965280]

[49]
Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail  2019; 21(11): 1415-22.
 [http://dx.doi.org/10.1002/ejhf.1478] [PMID: 31074184]

[50]
Martens P, Verbrugge FH, Dauw J, et al. Pre-treatment bicarbonate levels and decongestion by acetazolamide: The ADVOR trial. Eur Heart J  2023; 44(22): 1995-2005.
 [http://dx.doi.org/10.1093/eurheartj/ehad236] [PMID: 37138385]

[51]
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab  2018; 20(3): 479-87.
 [http://dx.doi.org/10.1111/dom.13126] [PMID: 29024278]

[52]
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation  2019; 140(7): e294-324.
 [http://dx.doi.org/10.1161/CIR.0000000000000691] [PMID: 31167558]

[53]
Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol  1996; 77(11): 1017-20.
 [http://dx.doi.org/10.1016/S0002-9149(97)89163-1] [PMID: 8644628]

[54]
From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med  2006; 119(7): 591-9.
 [http://dx.doi.org/10.1016/j.amjmed.2006.05.024] [PMID: 16828631]

[55]
Salvatore T, Pafundi PC, Galiero R, et al. The diabetic cardiomyopathy: The contributing pathophysiological mechanisms. Front Med  2021; 8: 695792.
 [http://dx.doi.org/10.3389/fmed.2021.695792] [PMID: 34277669]

[56]
MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J  2008; 29(11): 1377-85.
 [http://dx.doi.org/10.1093/eurheartj/ehn153] [PMID: 18413309]

[57]
de Miguel-Yanes JM, Gonzalo-Hernando C, Muñoz-Rivas N, Méndez-Bailón M, Cava-Valenciano F, Torres-Macho J. First plasma glucose value after urgent admission and in-hospital mortality in acutely decompensated heart failure. Heart Lung  2015; 44(2): 137-40.
 [http://dx.doi.org/10.1016/j.hrtlng.2014.11.006] [PMID: 25534479]

[58]
Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation  2009; 119(14): 1899-907.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.108.821843] [PMID: 19332465]

[59]
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med  2023; 389(12): 1069-84.
 [http://dx.doi.org/10.1056/NEJMoa2306963] [PMID: 37622681]

[60]
Villaschi A, Ferrante G, Cannata F, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: An updated systematic review and meta-analysis. Clin Res Cardiol  2024; 113(6): 898-909.
 [http://dx.doi.org/10.1007/s00392-023-02362-6] [PMID: 38252145]

[61]
Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation  2022; 146(4): 289-98.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059038] [PMID: 35766022]

[62]
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail  2020; 22(4): 713-22.
 [http://dx.doi.org/10.1002/ejhf.1713] [PMID: 31912605]

[63]
Rao VS, Planavsky N, Hanberg JS, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol  2017; 28(11): 3414-24.
 [http://dx.doi.org/10.1681/ASN.2016111178] [PMID: 28739647]

[64]
Sigurd B, Olesen KH, Wennevold A. The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Am Heart J  1975; 89(2): 163-70.
 [http://dx.doi.org/10.1016/0002-8703(75)90041-1] [PMID: 1090132]

[65]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2016; 37(27): 2129-200.
 [http://dx.doi.org/10.1093/eurheartj/ehw128] [PMID: 27206819]

[66]
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol  2010; 56(19): 1527-34.
 [http://dx.doi.org/10.1016/j.jacc.2010.06.034] [PMID: 21029871]

[67]
Brisco-Bacik MA, ter Maaten JM, Houser SR, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: A propensity analysis. J Am Heart Assoc  2018; 7(18): e009149.
 [http://dx.doi.org/10.1161/JAHA.118.009149] [PMID: 30371181]

[68]
Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J  2016; 37(27): 2105-14.
 [http://dx.doi.org/10.1093/eurheartj/ehw132] [PMID: 27130705]

[69]
Pandey AK, Bhatt DL, Cosentino F, et al. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J  2022; 43(31): 2931-45.
 [http://dx.doi.org/10.1093/eurheartj/ehac299] [PMID: 35713973]

[70]
Pitt B. Effectiveness of spironolactone added to an angiotensin- converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol  1996; 78(8): 902-7.
 [http://dx.doi.org/10.1016/S0002-9149(96)00465-1] [PMID: 8888663]

[71]
Girerd N, Pang PS, Swedberg K, et al. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial. Eur J Heart Fail  2013; 15(11): 1228-35.
 [http://dx.doi.org/10.1093/eurjhf/hft100] [PMID: 23787720]

[72]
Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na+/ Cl-cotransporter abundance. J Am Soc Nephrol  2001; 12(7): 1335-41.
 [http://dx.doi.org/10.1681/ASN.V1271335] [PMID: 11423562]

[73]
Hensen J, Abraham WT, Dürr JA, Schrier RW. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention. Am J Nephrol  1991; 11(6): 441-6.
 [http://dx.doi.org/10.1159/000168356] [PMID: 1840232]

[74]
van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol  1993; 71(3): A21-8.
 [http://dx.doi.org/10.1016/0002-9149(93)90241-4] [PMID: 8422000]

[75]
Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med  2014; 25(1): 67-72.
 [http://dx.doi.org/10.1016/j.ejim.2013.08.711] [PMID: 24070521]

[76]
Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure. JAMA Cardiol  2017; 2(9): 950-8.
 [http://dx.doi.org/10.1001/jamacardio.2017.2198] [PMID: 28700781]

[77]
Asakura M, Ito S, Yamada T, et al. Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): A multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J Cardiovasc Pharmacother  2022; 8(2): 108-17.
 [http://dx.doi.org/10.1093/ehjcvp/pvaa132] [PMID: 33175088]

[78]
Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA  2007; 297(12): 1332-43.
 [http://dx.doi.org/10.1001/jama.297.12.1332] [PMID: 17384438]

[79]
Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA  2007; 297(12): 1319-31.
 [http://dx.doi.org/10.1001/jama.297.12.1319] [PMID: 17384437]

[80]
Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail  2013; 19(6): 390-7.
 [http://dx.doi.org/10.1016/j.cardfail.2013.04.001] [PMID: 23743487]

[81]
Konstam MA, Kiernan M, Chandler A, et al. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol  2017; 69(11): 1409-19.
 [http://dx.doi.org/10.1016/j.jacc.2016.12.035] [PMID: 28302292]

[82]
Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol  2017; 69(11): 1399-406.
 [http://dx.doi.org/10.1016/j.jacc.2016.09.004] [PMID: 27654854]

[83]
Hodson DZ, Griffin M, Mahoney D, et al. Natriuretic response is highly variable and associated with 6-month survival. JACC Heart Fail  2019; 7(5): 383-91.
 [http://dx.doi.org/10.1016/j.jchf.2019.01.007] [PMID: 31047017]

[84]
Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol  2007; 49(6): 675-83.
 [http://dx.doi.org/10.1016/j.jacc.2006.07.073] [PMID: 17291932]

[85]
Srivastava M, Harrison N, Caetano AFSMA, Tan AR, Law M. Ultrafiltration for acute heart failure. Cochrane Libr  2022; 2022(1): CD013593.
 [http://dx.doi.org/10.1002/14651858.CD013593.pub2] [PMID: 35061249]

[86]
Elkayam U, Ng TMH, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure. Circulation  2008; 117(2): 200-5.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.107.737106] [PMID: 18172028]

[87]
Wan SH, Stevens SR, Borlaug BA, et al. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction. Circ Heart Fail  2016; 9(8): e002593.
 [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002593] [PMID: 27512103]

[88]
Liu C, Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J Card Fail  2014; 20(9): 625-9.
 [http://dx.doi.org/10.1016/j.cardfail.2014.06.353] [PMID: 24969700]

[89]
Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol  2007; 23(11): 865-8.
 [http://dx.doi.org/10.1016/S0828-282X(07)70840-1] [PMID: 17876376]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0113816128316596240625110337	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Diuretic Combination Therapy in Acute Heart Failure: An Updated Review

Abstract Play Pause

Related Journals

Related Books

Abstract